PEP-Therapy is a medical biotechnology company, which develops peptides as targeted therapies for severe diseases, with an initial focus on cancer.
PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Founded in January 2014, PEP-Therapy is building on research from Inserm (the French National Institute of Health), Institut Curie and Sorbonne University.
PEP-Therapy raised 3.1 M€ to date from Seventure Partners (Quadrivium 1 seed fund) and a personal investment from Dr Bernard Majoie former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).
Since incorporation, PEP-Therapy has also been awarded several non-dilutive grants:
to develop PEP-010 up to Phase I/II clinical trials (French Ministries of Industry and Research grant);
to develop new therapeutics for uveal melanoma (European Horizon 2020 grant).